The combination of Valproic acid and Coumarin-3-carboxylic acid inhibits lung cancer cell proliferation and migration by targeting EGFR/VEGFR2/c-Met-Akt-NF-kappaB signaling. This synergistic pair is a valuable research tool for investigating novel therapeutic strategies in oncology, with applications in both in vitro and in vivo cancer models.